"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Descriptor ID |
D014750
|
MeSH Number(s) |
D03.132.436.681.827.817 D03.633.100.473.402.681.827.817
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in this website by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 12 | 12 |
1995 | 1 | 11 | 12 |
1996 | 0 | 9 | 9 |
1997 | 0 | 9 | 9 |
1998 | 1 | 5 | 6 |
1999 | 0 | 6 | 6 |
2000 | 3 | 13 | 16 |
2001 | 1 | 9 | 10 |
2002 | 1 | 17 | 18 |
2003 | 6 | 12 | 18 |
2004 | 4 | 6 | 10 |
2005 | 0 | 7 | 7 |
2006 | 2 | 9 | 11 |
2007 | 2 | 11 | 13 |
2008 | 0 | 19 | 19 |
2009 | 2 | 16 | 18 |
2010 | 4 | 20 | 24 |
2011 | 0 | 12 | 12 |
2012 | 2 | 13 | 15 |
2013 | 1 | 20 | 21 |
2014 | 1 | 22 | 23 |
2015 | 2 | 28 | 30 |
2016 | 2 | 22 | 24 |
2017 | 3 | 18 | 21 |
2018 | 3 | 22 | 25 |
2019 | 4 | 15 | 19 |
2020 | 6 | 18 | 24 |
2021 | 1 | 15 | 16 |
2022 | 0 | 15 | 15 |
2023 | 1 | 10 | 11 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vincristine" by people in Profiles.
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leuk Lymphoma. 2023 Dec; 64(14):2258-2268.
-
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer. Mol Cancer Ther. 2023 08 01; 22(8):962-975.
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 09; 29(9):548-555.
-
Impact of triple intrathecal prophylaxis in acute lymphoblastic leukemia adults receiving HyperCVAD: A COVID-19 practice change. Eur J Haematol. 2023 Jul; 111(1):154-160.
-
Vincristine/irinotecan/temsirolimus upfront window treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee. Pediatr Blood Cancer. 2023 07; 70(7):e30365.
-
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Adv. 2023 04 11; 7(7):1137-1145.
-
Treatment outcomes of extraskeletal Ewing sarcoma. J Surg Oncol. 2023 Jul; 128(1):105-110.
-
SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches. Clin Lymphoma Myeloma Leuk. 2023 04; 23(4):238-243.